Measuring progress towards universal health coverage.
This sixth edition of Health at a Glance Asia/Pacific presents a set of key indicators of health status, the determinants of health, health care resources and utilisation, health care expenditure and financing and quality of care across 27 Asia-...Pacific countries and territories. It also provides a series of dashboards to compare performance across countries and territories, and a thematic analysis on the impact of the COVID-19 outbreak on Asia/Pacific health systems.
more
21 January 2022
The overall threat posed by Omicron largely depends on four key questions: (i) how transmissible the variant is; (ii) how well vaccines and prior infection protect against infection, transmission, clinical disease and death; (iii) how virulent the variant is compared to other varian...ts; and (iv) how populations understand these dynamics, perceive risk and follow control measures, including public health and social measures (PHSM).
more
The WHO Ebola Virus Disease (EVD) Clinical management: living guidance contains the Organization’s most up-to-date recommendations for the clinical management of people with EVD. Providing guidance that is comprehensive and holistic for the optimal care of patients with EVD throughout their il...lness is important.
The living guidance is available in both pdf format (via the ‘Download’ button) and via an online platform in both French and English, and is updated regularly as new evidence emerges.
This first version of the Clinical management for EVD living guidance contains four new recommendations regarding use of therapeutics for EVD, this includes two strong recommendations for the use of monoclonal antibody therapies. This new living guideline is written to accompany the optimized supportive care (oSoC) for EVD standard operating procedures (5, 6). The living guideline aims to summarize high quality evidence for EVD therapeutics and make recommendations for their use.
more
PLoS One. 2012; 7(4): e29656.
Published online 2012 Apr 20. doi: 10.1371/journal.pone.0029656
WHO has developed this manual in order to strengthen the laboratory diagnosis and virological surveillance of influenza infection.
This document aims to provide interim guidance for microbiology and virology experts, other laboratory professionals, laboratory managers, infectious disease programme managers, public health professionals and other stakeholders that provide primary, confirmatory or advanced testing for SARS-CoV-2, ...including genomic sequencing, or are involved in making decisions on establishing or scaling up capability and capacity to detect and characterize circulating SARS-CoV-2 variants.
more
Current Tropical Medicine Reports (2018) 5:247–256 https://doi.org/10.1007/s40475-018-0166-2 .Purpose of the Review Buruli ulcer (BU) is a necrotizing and disabling cutaneous disease caused by Mycobacterium ulcerans, one of the skin-related neglected tropical diseases (skin NTDs). This article aim...s to review the current knowledge of this disease and challenges ahead.
more
These guidelines provide evidence-based guidance on the use of peripartum antiviral prophylaxis in HBsAg-positive pregnant women for the prevention of mother-to-child transmission of HBV.
This rapid compilation of data analyses provides a ‘stock-take’ of social science and behavioural data related to the on-going outbreak of Ebola in North Kivu, South Kivu and Ituri provinces. Based on data gathered and analysed by organisations working in the Ebola response and in the region mor...e broadly, it explores convergences and divergences between datasets and, when possible, differences by geographic area, demographic group, time period and other relevant variables. Data sources are listed at the end of the document.
more
J Infect Dis. (2012) 206 (suppl. 1): S61-S67
Influenza data gaps in sub-Saharan Africa include incidence, case fatality, seasonal patterns, and associations with prevalent disorders. The authors found that the burden of influenza was small during 2007–2010 in this paediatric hospital in Kenya. In...fluenza A virus subtype H3N2 predominated, and 2009 pandemic influenza A virus subtype H1N1 had little impact
more
GUIDELINES FOR AWWs/ASHAs/ANMs/PRIs
La Guinée a été le point zéro de la flambée récente de la maladie à virus Ebola. Le taux de mortalité attribuée à Ebola en Guinée était de 66 %, nettement plus élevé que les taux des deux autres pays ouest-africains les plus affectés : la Sierra Leone (32 %) et le Liberia (45 %). Face... à la fermeture des cliniques, aux patients qui évitent les établissements sanitaires de peur de contracter Ebola et aux patients présentant des symptômes semblables à ceux d’Ebola qu’on renvoie chez eux, les experts en matière de santé s’inquiètent que d’autres maladies, telles que le paludisme, la pneumonie et la fièvre typhoïde, ne seront pas soignées, et que des soins de routine comme ceux qui favorisent la santé maternelle et infantile ne seront pas fournis.
more
At the time of writing, the novel coronavirus pandemic had reached every region of the world, with millions of infections globally and untold disruptions to nearly every aspect of daily life.
Integrated Management of pregnancy and childbirth
Cette note stratégique porte spécifiquement sur le Grand Nord : soit les territoires de Beni et de Lubero au nord du Nord-Kivu constituant l’épicentre de la flambée épidémiquee. D’autres enquêtes participatives doivent être menées auprès des populations touchées, mais étant donné l...actuelle transmission du virus, la priorité a été accordée à la communication des considérations clées et des recommandations immédiates.
more
Initial public health responses to control the pandemic focused on promoting protective behaviors among the general population, including frequent hand washing, physical distancing and the use of face masks in public spaces However, many saw these only as interim measures to reduce the spread of the... virus and hopes for a return to a sense of ‘ rested on the development of a safe and effective vaccine.
more
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).